Luke Baldelli

Luke Baldelli

Auto-generated profile, based on publicly available information

Luke Baldelli

Department of Medicine,University of North Carolina School of Medicine,Chapel Hill,NC

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Hepatology
Verified
Journal Article
Open access
TMThomas Marjot
Thomas Marjot
GBGustav Buescher
Gustav Buescher
MSMarcial Sebode
Marcial Sebode
EBEleanor Barnes
Eleanor Barnes
ABA. Sidney Barritt
A. Sidney Barritt
ALAnsgar W. Lohse
Ansgar W. Lohse
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH). Data for patients with AIH and SARS-CoV-2 infection were combined from 3 international reporting registries and outcomes were compared to those in patients with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD). Between 25th March and 24th October 2020, data were collected for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) patients with AIH were taking ≥1 immunosuppressive drug. There were no differences in rates of major outcomes between patients with AIH and non-AIH CLD, including hospitalization (76% vs. 85%; p = 0.06), intensive care unit admission (29% vs. 23%; p = 0.240), and death (23% vs. 20%; p = 0.643). Factors associated with death within the AIH cohort included age (odds ratio [OR] 2.16/10 years; 1.07–3.81), and Child-Pugh class B (OR 42.48; 4.40–409.53), and C (OR 69.30; 2.83–1694.50) cirrhosis, but not use of immunosuppression. Propensity score matched (PSM) analysis comparing patients with AIH with non-AIH CLD demonstrated no increased risk of adverse outcomes including death (+3.2%; -9.2%–15.7%). PSM analysis of patients with AIH vs. non-CLD (n = 769) demonstrated increased risk of hospitalization with AIH (+18.4%; 5.6–31.2%), but equivalent risk of all other outcomes including death (+3.2%; -9.1%–15.6%). Patients with AIH were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease. Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from 3 large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.

21 October 2021 in Liver Transplantation
Verified
Journal Article
Closed access
SLSarah R. Lieber
Sarah R. Lieber
HKHannah P. Kim
Hannah P. Kim
LBLuke Baldelli
Luke Baldelli
RNRebekah Nash
Rebekah Nash
RTRandall Teal
Randall Teal
DEDonna M. Evon
Donna M. Evon
Survivorship after liver transplantation (LT) is a novel concept providing a holistic view of the arduous recovery experienced after transplantation. We explored components of early survivorship including physical, emotional, and psychological challenges to identify intervention targets for improving the recovery process of LT recipients and caregivers. A total of 20 in‐person interviews were conducted among adults 3 to 6 months after LT. Trained qualitative research experts conducted interviews, coded, and analyzed transcripts to identify relevant themes and representative quotes. Early survivorship comprises overcoming (1) physical challenges, with the most challenging experiences involving mobility, driving, dietary modifications, and medication adherence, and (2) emotional and psychological challenges, including new health concerns, financial worries, body image/identity struggles, social isolation, dependency issues, and concerns about never returning to normal. Etiology of liver disease informed survivorship experiences including some patients with hepatocellular carcinoma expressing decisional regret or uncertainty in light of their post‐LT experiences. Important topics were identified that framed LT recovery including setting expectations about waitlist experiences, hospital recovery, and ongoing medication requirements. Early survivorship after LT within the first 6 months involves a wide array of physical, emotional, and psychological challenges. Patients and caregivers identified what they wish they had known prior to LT and strategies for recovery, which can inform targeted LT survivorship interventions.

2 December 2022 in Gut and Liver
Verified
Journal Article
Open access
PDF file
LBLuke Baldelli
Luke Baldelli
TMThomas Marjot
Thomas Marjot
EBEleanor Barnes
Eleanor Barnes
ABA. Sidney Barritt
A. Sidney Barritt
GWGwilym J. Webb
Gwilym J. Webb
AMAndrew M. Moon
Andrew M. Moon
Luke Baldelli, Thomas Marjot, Eleanor Barnes, A. Sidney Barritt, Gwilym J. Webb, and Andrew M. Moon. Gut and Liver 2023;17:12-23. https://doi.org/10.5009/gnl220327

17 February 2023 in Liver Transplantation
Verified
Journal Article
Closed access
SLSarah R. Lieber
Sarah R. Lieber
LBLuke Baldelli
Luke Baldelli
HKHannah P. Kim
Hannah P. Kim
RNRebekah P. Nash
Rebekah P. Nash
ARAlvaro Noriega Ramirez
Alvaro Noriega Ramirez
ASAmit Singal
Amit Singal
Understanding survivorship experiences at different stages postliver transplantation (poat-LT) is essential to improving care. Patient-reported concepts including coping, resilience, post-traumatic growth (PTG), and anxiety/depression, have been implicated as important predictors of quality of life and health behaviors after LT. We aimed to descriptively characterize these concepts at different post-LT survivorship stages. This cross-sectional study featured self-reported surveys measuring sociodemographic, clinical characteristics, and patient-reported concepts including coping, resilience, PTG, anxiety, and depression. Survivorship periods were categorized as early (1 y or below), mid (1–5 y), late (5–10 y), and advanced (10 y or above). Univariable and multivariable logistic and linear regression modeling examined factors associated with patient-reported concepts. Among 191 adult LT survivors, the median survivorship stage was 7.7 years (interquartile range: 3.1–14.4) and median age was 63 years (range: 28–83); most were male (64.2%) and Caucasian (84.0%). High PTG was more prevalent in the early survivorship period (85.0%) than late survivorship (15.2%). High trait resilience was only reported by 33% of survivors and associated with higher income. Lower resilience was seen among patients with longer LT hospitalization stays and late survivorship stages. About 25% of survivors had clinically significant anxiety and depression, which was more frequent among early survivors and females with pre-LT mental health disorders. In multivariable analysis, factors associated with lower active coping included survivors ≥65 years, non-Caucasian race, lower levels of education, and nonviral liver disease. In a heterogeneous cohort including early and late LT survivors, there was variation in levels of PTG, resilience, anxiety, and depression at different survivorship stages. Factors associated with positive psychological traits were identified. Understanding determinants of LT survivorship has important implications for how we should monitor and support LT survivors.

31 July 2021 in Liver Transplantation
Verified
Journal Article
Closed access
SLSarah R. Lieber
Sarah R. Lieber
HKHannah P. Kim
Hannah P. Kim
LBLuke Baldelli
Luke Baldelli
RNRebekah Nash
Rebekah Nash
RTRandall Teal
Randall Teal
DEDonna M. Evon
Donna M. Evon